Mode
Text Size
Log in / Sign up
Phase 3 N=195 Randomized Double-blind Supportive Care

Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer

Breast Cancer · Vaginal Dryness

Enrolled (actual)
195
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics — 63.6; 55.8; 66.0 units on a scale — p=0.1675

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
pilocarpine hydrochloride (Drug); placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Alliance for Clinical Trials in Oncology
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics
63.6; 55.8; 66.0 0.1675
SECONDARY
Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) 3.0
2; 14; 17; 12; 21; 29 0.002 sig
SECONDARY
Average AUC Summary Statistics for the Impact of Vaginal Dryness for Activities of Daily Living
87.9; 87.1; 87.0; 85.4; 75.8; 81.8
SECONDARY
Change From Baseline to Week 6 on the Impact of Vaginal Dryness for Activities of Daily Living Scores
17.8; 16.0; 16.1; 18.3; 17.8; 18.9

Summary

RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with breast cancer. PURPOSE: This randomized phase III trial is studying pilocarpine to see how well it works compared to a placebo in treating vaginal dryness in patients with breast cancer.

Eligibility Criteria

Required Characteristics:

  • Adult post menopausal women or women with no childbearing potential (≥ 18 years) with a history of breast cancer (currently no evidence of disease) or women who do not want to take vaginal estrogen for a fear of an increased risk of breast cancer. Postmenopausal status will be determined by the primary physician.
  • Significant vaginal complaints defined as persistent vaginal dryness and/or itching of sufficient severity to make a patient desire therapeutic intervention. Symptoms should have been present ≥ 2 months prior to randomization.
  • Life expectancy > 6 months
  • Ability to complete questionnaire(s) by themselves or with assistance.

Contraindications:

  • Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤2 months prior to randomization or plans to initiate or discontinue any of these medications during the 6-week study.
  • Active vaginal infection
  • Concurrent chemotherapy
  • Acute iritis
  • Current or past use of pilocarpine (regardless of purpose)
  • Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Lubricants used during sexual intercourse are permitted.
  • Use of any vaginal preparations ≤ 1 week prior to study entry (Exception: If patient has used vaginal preparations during the previous week but will stop, then they can be placed on study with plans to start with pretreatment questionnaire one week later). Note: Lubricants used during sexual intercourse are permitted.
  • Current (≤ 4weeks prior to randomization), or planned during the study period, use of any estrogen product.
  • A diagnosis of asthma, COPD, CAD or narrow angle glaucoma, or known cholelithiasis.
  • Hepatic or renal insufficiency defined as a history of an elevation of SGOT ≥1.5 x ULN or creatinine ≥ 1.5 x ULN within the past year.
  • Concurrent use of other anticholinergics
  • Use of pharmacologic soy preparations
  • Known history of cardiac arrhythmia. (Patients with occasional PVC's or PAC's that do not require treatment are eligible.)
  • Prior or concurrent pelvic radiation therapy
  • Prior radical pelvic surgery (TAH/BSO is allowed)
  • Use of beta adrenergic antagonists
  • Diagnosis of any of the following conditions:
  • Vulvar and vaginal dysplasia
  • Essential vulvodynia
  • Vulvar vestibulitis
  • Vaginal prolapse
  • Bartholin cyst/abscess
  • History of Bartholin gland surgery
  • Lichen sclerosis
  • Lichen planus of the vulvovaginal region
  • Desquamative vaginitis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00343382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search